BIND Therapeutics: Cowen and Company Healthcare Conference (BIND Therapeutics) - Mar 5, 2015 - “Phase 2 Data Provide Clear Differentiation from Docetaxel in Squamous Histology NSCLC”; “Disease control rate of 66%”; “Interim overall survival of 11.1 months”; “Favorable safety profile with 56% of patients receiving 4 or more cycles of BIND-014”; “Compares favorably with agents that have completed phase 3 trials”
P2 data • Non Small Cell Lung Cancer • Oncology
|